An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
Excerpt:
...In order to include only IDO1 positive (≥5% expression of tumor cells) and non T-cell infiltrated tumors (<1% T cells infiltrating the tumor bed)...
Identification of mRNA signatures that predict response to immunotherapy in melanoma patients
Published date:
11/08/2019
Excerpt:
Among other genes, IDO1 mRNA was also found to be significantly associated with longer PFS (P < 0.01, False discovery rate (FDR) = 0.18) and OS (P < 0.01, FDR = 0.052).